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Chordomas are rare primary malignant bone tumors arising from embryonal notochord 
remnants of the axial skeleton. Chordomas commonly recur following surgery and radio-
therapy, and there is no effective systemic therapy. Previous studies implicated receptor 
tyrosine kinases, including epidermal growth factor receptor (EGFR) and type 1 insulin-like 
growth factor receptor (IGF-1R), in chordoma biology. We report an adult female patient 
who presented in 2003 with spinal chordoma, treated with surgery and radiotherapy. She 
underwent further surgery for recurrent chordoma in 2008, with subsequent progression 
in pelvic deposits. In June 2009, she was recruited onto the Phase I OSI-906-103 trial of 
EGFR inhibitor erlotinib with linsitinib, a novel inhibitor of IGF-1R/insulin receptor (INSR). 
Treatment with 100 mg QD erlotinib and 50 mg QD linsitinib was well-tolerated, and 
after 18 months a partial response was achieved by RECIST criteria. From 43 months, 
a protocol modification allowed intra-patient linsitinib dose escalation to 50 mg BID. The 
patient remained stable on trial treatment for a total of 5 years, discontinuing treatment in 
August 2014. She subsequently experienced further disease progression for which she 
underwent pelvic surgery in April 2015. Analysis of DNA extracted from 2008 (pre-trial) 
tissue showed that the tumor harbored wild-type EGFR, and a PIK3CA mutation was 
detected in plasma, but not tumor DNA. The 2015 (post-trial) tumor harbored a mutation 
of uncertain significance in ATM, with no detectable mutations in other components of 
a 50 gene panel, including EGFR, PIK3CA, and TP53. By immunohistochemistry, the 
tumor was positive for brachyury, the molecular hallmark of chordoma, and showed 
weak– moderate membrane and cytoplasmic EGFR. IGF-1R was detected in the plasma 
membrane and cytoplasm and was expressed more strongly in recurrent tumor than 
the primary. We also noted heterogeneous nuclear IGF-1R, which has been linked with 
sensitivity to IGF-1R inhibition. Similar variation in IGF-1R expression and subcellular 
localization was noted in 15 further cases of chordoma. In summary, this exceptionally 
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INtRoDUCtIoN
Chordomas are rare primary malignant bone tumors arising from 
primitive notochord remnants, and account for ~17% of primary 
malignant bone tumors of the axial skeleton (1). Chordomas 
express the transcription factor brachyury (T) that directs noto-
chord development (2). Germ-line duplication of the brachyury 
gene is associated with familial chordoma, copy number gain is 
reported in sporadic chordomas, and common genetic variants in 
brachyury have recently been associated with both familial and 
sporadic chordomas (3–6).
Clinically, there is approximately equal distribution between 
cranial, spinal, and sacral origin, with risk of local recurrence in 
~45%, metastasis in ~30%, and median survival of 6.3 years (7–9). 
The mainstay of treatment is local therapy in the form of surgery 
and radiotherapy, ideally with proton beam therapy (9). Invasion 
of adjacent muscles is common, compromising the likelihood 
of complete surgical resection, and extent of resection, surgical 
margins, tumor grade and proton therapy are the most important 
predictors of recurrence and survival (10–12). Although chordo-
mas are typically indolent, recurrent tumors can pursue a more 
aggressive course with distant metastases. In a series of 18 sacral 
chordoma patients, 12 patients experienced recurrence, and of 
those, 7 died in median 5.4 months (range 4–40 months) after the 
recurrence (10). Chordomas are resistant to chemotherapy, and 
there are no licensed options for systemic therapy, although several 
targeted agents have induced responses in individual cases (13).
DesCRIptIoN oF Case
The patient is a 65-year-old non-smoker who presented in mid-
2003 with a 9-month history of lower back pain. Magnetic reso-
nance imaging (MRI) revealed replacement of the L4 vertebra by 
a lobulated tumor that invaded the spinal canal, encroaching on 
the cauda equina. MRI and computed tomography (CT) scans 
showed no evidence of primary tumor elsewhere. She underwent 
biopsy under fluoroscopic control followed by surgery on 16th 
July 2003. The procedure involved radical tumor resection 
with insertion of an intervertebral cage containing a biphasic 
calcium phosphate ceramic (Triosite). Histological examina-
tion (Figures  1A,B) showed tumor composed predominantly 
of physaliphorous cells arranged in nests and set in a mucinous 
matrix. There was considerable nuclear pleomorphism and 
hyperchromasia and occasional atypical mitoses. Tumor cells 
were positive for cytokeratins and S100 (not shown), and also 
for brachyury (Figure 1C), the molecular hallmark of chordoma 
(2). The tumor infiltrated soft tissue and extended to the surgical 
margins. Proton therapy being unavailable (14), she underwent a 
course of adjuvant photon beam radiotherapy to the lumbar spine 
(L3–L5 inclusive, 50 Gy total dose in 30 fractions).
durable response suggests that there may be merit in evaluating combined IGF-1R/
INSR and EGFR inhibition in patients with chordomas that recur following failure of local 
treatment.
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From April 2007, the patient experienced recurrent pain, 
weakness, and altered sensation in the lower limbs. Initial MRI 
scans were equivocal for tumor recurrence but, in August 2007, 
showed definite evidence of recurrence to the left of the fourth 
lumbar vertebral body, eroding the superior end-plate and the 
posterosuperior border of L5 vertebral body. She experienced 
further clinical and radiological progression, including an 
acute episode of paraplegia in December 2007, and in February 
2008, she underwent major revision surgery. Laparotomy 
revealed considerable recurrent tumor behind the body of 
L4 with bleeding into the spinal canal at this level, and tumor 
infiltrating the psoas muscles, also with hemorrhagic change. She 
underwent a debulking procedure with anterior vertebrectomy 
and anterior and posterior fusion, leaving residual tumor in the 
psoas muscles. Histopathological analysis confirmed recurrent 
brachyury- positive chordoma in the L4 vertebral body, epidural 
surface, psoas muscles bilaterally, and left abdominal wall. Post-
operatively, there was gradual recovery of power in the lower 
limbs, although with persistent altered sensation in the legs and 
loss of knee and ankle reflexes. MRI scans in March 2009 showed 
further evidence of progression, prompting referral to our Early 
Phase Clinical Trials Unit in June 2009.
The patient was recruited onto the Phase I OSI-906-103 trial, 
evaluating linsitinib (OSI-906), a novel inhibitor of the type 1 
insulin-like growth factor receptor (IGF-1R) and insulin recep-
tor (INSR), in combination with the epidermal growth factor 
receptor (EGFR) inhibitor erlotinib (15). Initial investigations 
showed that hematology, renal and liver function, coagula-
tion screen, fasting glucose, and HbA1c were all normal, with 
LDH 232 U/L (normal 100–190 U/L). Baseline CT scan in June 
2009 showed extensive bone destruction and surgical fixation 
involving the lumbosacral spine. MRI, on the same date, showed 
recurrent tumor with measurable components within the right 
iliopsoas muscle (mid-right psoas 35 mm, Figure 2A; right side 
of L3/4, 29 mm) and to the left side of the intervertebral device at 
L4 (35 mm). The patient was treated on the S2 (daily linsitinib) 
schedule (15), receiving 50 mg linsitinib QD from 30th June 2009, 
with addition of 100 mg erlotinib QD after 1 week. The treatment 
was well-tolerated aside from dry skin (grade 1), abnormal hair 
and eyelash growth (grade 1), and bilateral hallux paronychia 
(grade 2 at worst), attributed to erlotinib, and diarrhea (grade 1), 
attributed to both agents. There was no evidence of hematologic 
toxicity, hyperglycemia, or hyperinsulinemia, and no biochemi-
cal abnormalities with the exception of creatine kinase, which 
was measured for the first time in March 2012 and was elevated 
(333  U/L, normal range 24–195  U/L; grade 1 elevation), with 
subsequent persistent elevation (350–520, grade 2) probably 
attributable to psoas muscle involvement.
Sequential MRI scans revealed initial disease stabilization, 
with gradual improvement to partial response by response 
FIGURe 2 | objective response of chordoma to linsitinib and erlotinib. 
(a) Baseline MRI pelvis in June 2009, showing right iliopsoas deposit. 
Additional marker lesions were measured in the oblique right psoas (29 mm) 
and left paravertebral region (35 mm) giving a sum for the three lesions of 
99 mm. (B) Response MRI of December 2010 showing reduction in size of 
right iliopsoas deposit. (C) Graph: monitoring of serial MRI scans by RECIST 
criteria, represented as the sum of measurements of the three marker lesions 
described in (a). After 44 months (February 2013), these three lesions were 
no longer clearly measurable, and a new marker lesion (left external iliac, 
57 mm) was selected to monitor response to linsitinib dose escalation from 
50 mg QD to BID.
FIGURe 1 | Histological appearance of chordoma. (a,B) Sections of 
primary tumor stained with hematoxylin and eosin (H&E). (C) Parallel section 
stained for brachyury. Scale bar: 50 μm.
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left external iliac deposit (Figure 2C). From early 2014, she expe-
rienced gradual worsening of right leg weakness. Although there 
was no major change in the dimensions of the monitored marker 
lesion, there was evidence of slow progression in non-marker 
lesions including deposits in the right psoas and left iliopsoas on 
MRI scan and left inguinal and external iliac lymphadenopathy 
visible on CT scan. She came off study in August 2014 after 
61  months of trial treatment, and subsequently experienced 
further symptomatic deterioration accompanied by progression 
in the left external iliac deposit (Figure 2C), prompting further 
pelvic surgery in April 2015.
Analysis of tumor tissue was conducted under study 07/
H0606/120, approved by National Research Ethics Service (NRES) 
Committee South Central-Oxford C. Formalin-fixed, paraffin-
embedded (FFPE) tumor blocks from the 2008 surgery yielded a 
small amount of genomic DNA for mutation analysis. No variants 
were detected in EGFR codons 18, 19, and 21 (with technical failure 
of the exon 20 assay), KRAS, BRAF, or PIK3CA, whereas analysis 
of plasma DNA revealed E542K mutation in exon 9 of PIK3CA, 
as reported in Ref. (15). DNA was also extracted from macro-
dissected FFPE tumor from the 2015 resection and was tested 
for mutation hotspots by targeted massively parallel sequencing 
(http://www.oxford-translational-molecular-diagnostics.org.
uk/). This analysis showed no evidence of mutation in EGFR, 
evaluation criteria in solid tumors (RECIST) in December 2010, 
after 18 months of study treatment (Figures 2B,C). In February 
2013, following protocol amendment to allow intra-patient dose 
escalation, the linsitinib dose was increased to 50 mg BID. This 
treatment was monitored on a new marker lesion (left external 
iliac deposit, 57  mm), since the previously monitored marker 
lesions were no longer evaluable. The patient continued on linsi-
tinib 50 mg BID and erlotinib 100 mg QD with stabilization of the 
FIGURe 3 | Chordoma of trial patient contains prominent nuclear 
IGF-1R and membrane eGFR. (a) The specificity of IGF-1R and EGFR IHC 
was tested using sections of formalin-fixed, paraffin-embedded MCF7 breast 
cancer cells (high IGF-1R, low EGFR) and SKUT-1 leiomyosarcoma cells 
(IGF-1R deficient, EGFR positive). (B) Sections of chordoma from the trial 
patient were stained for IGF-1R and EGFR, including primary tumor from 
2003, and recurrent tumor from 2008 (pre-trial) and 2015 (post-trial). Scale 
bar: 50 μm.
FIGURe 4 | Brain and spinal chordomas contain IGF-1R with variable 
membrane, cytoplasmic, and nuclear positivity. IGF-1R IHC was 
performed on the primary tumor, 3 tumor blocks from the 2008 recurrence 
and one block from the 2015 (post-trial) recurrence of the trial patient, and 15 
additional chordoma cases. Each tumor was scored for IGF-1R signal in the 
membrane, cytoplasm, and nucleus for the percentage showing zero (0), 
weak (1), moderate (2), or heavy (3) IGF-1R intensity, giving a maximum 
histoscore in each subcellular location of 100% × 3 = 300.
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TP53, PTEN, PIK3CA, PDGFRA, KRAS, NRAS, BRAF, KIT, 
ERBB4, FGFR1, ERBB2, MET, FGFR3, FLT3, GNAS, SMARCB1, 
CTNNB1, CDKN2A, ABL1, NOTCH1, PTPN11, SMO, SMAD4, 
VHL, NPM1, MPL, CSF1R, HRAS, JAK3, AKT1, IDH1, CDH1, 
FGFR2, SRC, KDR, ALK, JAK2, MLH1, RB1, HNF1A, APC, RET, 
STK11, FBXW7, EZH2, GNA11, GNAQ, and IDH2. A mutation 
of uncertain clinical significance was detected in the ATM gene 
[c.9031A>G, p.(M3011V), NM_000051.3].
Immunohistochemical (IHC) analysis was conducted on 
FFPE tumor to investigate IGF-1R and EGFR expression, using 
an IGF-1R IHC protocol recently optimized for sensitivity and 
specificity (16–18). Initial testing in FFPE control cell line pellets 
confirmed the specificity of the IGF-1R and EGFR antibodies in 
IHC (Figure 3A). Both the primary and recurrent chordoma of 
the trial patient contained patchy IGF-1R signal that was weaker 
in the primary biopsy and one of the blocks (C, psoas deposit) 
of recurrent tumor and stronger and more uniformly positive in 
two further blocks (A, B; deposits in connective tissue) from the 
2008 (pre-trial) recurrence (Figure  3B). In all tumor samples, 
there was detectable membrane and cytoplasmic IGF-1R, with 
clearly apparent nuclear positivity that showed heterogeneity 
between different regions of tumor, and was most evident in the 
2008 (pre-trial) recurrence. The tumor also contained detectable 
EGFR, with weak/moderate membrane and cytoplasmic signal 
but no nuclear positivity (Figure  3B). Analysis of tumor from 
the 2015 (post-trial) recurrence showed that EGFR and IGF-1R 
were still detectable, but with reduced intensity compared with 
the 2008 recurrence, and reduced nuclear IGF-1R (Figure 3B).
To determine the extent to which these appearances are repre-
sentative, we performed IGF-1R IHC on 15 additional chordoma 
cases (Figure 4), including 3 cases originating in the sacrococcy-
geal region and 12 cases arising in the brain. All were positive for 
brachyury (not shown), with heterogeneity of IGF-1R expression 
and subcellular localization, similar to that seen in our trial case. 
We scored IGF-1R in the membrane, cytoplasm, and nucleus, 
assessing the percentage of each sample showing zero (0), weak 
(1), moderate (2), or heavy (3) IGF-1R intensity. Figure 4 shows 
the sum of IGF-1R scores in each subcellular location, indicating 
that the variation in IGF-1R expression and localization in our 
trial case had parallels in other chordoma cases.
DIsCUssIoN
Previous reports have implicated receptor tyrosine kinase (RTK) 
signaling in the biology of chordomas (19). A recent study 
reported that most chordomas express multiple RTKs, including 
PDGFR isoforms, EGFR, HER2, c-MET, and KIT. Like IGF-1R, 
all of these RTKs signal via AKT to enhance tumor cell growth 
and survival (20), and the level of AKT phosphorylation was 
found to correlate with poor survival (21). In several series, which 
have been of limited size due to the rarity of this tumor type, 
imatinib-induced blockade of PDGFR and KIT has shown mod-
est activity as monotherapy (14, 22–24), with evidence of activity 
in combination with rapamycin (25). EGFR expression has been 
detected by IHC in ~70% of chordomas, with high level EGFR 
copy number gain in 40%, and suppression of in vitro chordoma 
cell growth by a tyrphostin EGFR inhibitor (26). As in other 
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reported cases of chordoma, our patient’s tumor lacks the EGFR 
mutations that are associated with response to EGFR inhibition in 
lung cancer (26, 27). A recent Phase II trial of lapatinib reported 
stable disease as best response (28), but there are four clinical 
case reports of objective responses to EGFR inhibition using 
erlotinib, gefitinib, and/or cetuximab (29–32). Our patient was 
taking 100 mg erlotinib daily, below the recommended dose of 
150 mg, although there is reported overlap in drug exposure in 
patients treated at 100 or 150 mg erlotinib daily (33).
Recent studies have investigated the contribution of the IGF 
axis to chordoma biology. IGF-binding protein-2 (IGFBP-2) was 
among the genes found to be upregulated in chordoma compared 
with benign intervertebral disk (34). In other cellular models 
and tumor types IGFBP-2 has been shown to promote tumor 
growth and metastasis (35). Activation of IGF-1R and INSR is 
reportedly detectable in ~40% of chordomas and is associated 
with significant reduction in disease-free survival (36). Another 
IHC study detected IGF-1R, IGF-1, and IGF-2 in 76, 90, and 50% 
of chordomas, respectively, with one-third showing moderate 
to strong IGF-1R, as in our study, and a significant correlation 
between IGF-1R staining intensity and primary tumor volume 
(37). This study detected membrane and cytoplasmic IGF-1R but 
no nuclear signal (37), using an antibody to the alpha subunit 
of IGF-1R, which we have found is capable of detecting nuclear 
IGF-1R but generally gives stronger membrane signal (16). 
Prominent IGF-1R nuclear positivity in the tumor of our patient 
is of interest, given our previous finding that nuclear IGF-1R 
in prostate cancer models is induced by ligand and blocked by 
IGF-1R kinase inhibition (16). This raises the question as to 
whether the presence of nuclear IGF-1R indicates strong IGF axis 
activation, perhaps to the point where the tumor is dependent on 
IGF signaling. Supporting this concept, the tumors of sarcoma 
patients who derived benefit from therapeutic IGF-1R antibody 
were reported to show exclusively nuclear IGF-1R (38).
Genetic analysis of human chordomas has identified several 
additional changes that are implicated in tumorigenesis and 
could be relevant to response to therapy. First, PIK3CA (E545K) 
was detected in 1 of 45 patients (39) and was also detected in 
the circulating DNA of our patient, although its significance is 
unclear, since the same mutation was not detected in the tumor. 
PIK3CA mutation might be predicted to mediate resistance to 
inhibition of signaling at the RTK level, and indeed experimental 
and clinical data suggest this is the case for EGFR inhibition (40, 
41). The same may not be true for IGF signaling: it is known 
that PIK3CA-mutated breast cancer cells remain responsive to 
IGF stimulation and are growth delayed by IGF-1R inhibition 
(42–44). Second, studies of genetic alterations in chordoma 
identified mutation or loss of the cell cycle regulator CDKN2A 
(39, 45), which is of interest since we identified CDKN2C and 
CDKN3 as hits in a screen for proteins whose depletion enhances 
sensitivity to IGF-1R inhibition (46). Finally, our patient’s tumor 
harbored wild-type TP53, reported by our group and others to 
be associated with response to small molecule IGF-1R inhibitors 
including linsitinib in preclinical studies (47, 48).
In conclusion, we report a durable objective response to 
linsitinib and erlotinib in a patient with spinal chordoma that had 
recurred following failure of local treatment. Factors that may 
be relevant to the response include TP53, EGFR and PIK3CA 
status and the presence of nuclear IGF-1R, which may signify 
dependence on IGF-1R and sensitivity to IGF axis inhibition. We 
suggest that trials incorporating assessment of these parameters 
should evaluate the effects of combined IGF-1R/INSR and EGFR 
inhibition in patients with recurrent chordomas.
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